Anavex Life Sciences Corp.
AVXL
Price:
$11
Market Cap:
$932.75M
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the trea...[Read more]
Industry
Biotechnology
IPO Date
2006-08-02
Stock Exchange
NASDAQ
Ticker
AVXL
PE Ratio
[-21.15]
ROE
[-30.63%]
Current Ratio
[12.04]
Dividend Yield
[0%]
Enterprise Value
[793.99M]
Dividend History
The ROE as of December 2024 (TTM) for Anavex Life Sciences Corp. (AVXL) is -30.63%
According to Anavex Life Sciences Corp.’s latest financial reports and current stock price. The company's current ROE is -30.63%. This represents a change of 298.71% compared to the average of -7.68% of the last 4 quarters.
Anavex Life Sciences Corp. (AVXL) Historical ROE (quarterly & annually)
How has AVXL ROE performed in the past?
The mean historical ROE of Anavex Life Sciences Corp. over the last ten years is -82.30%. The current -30.63% ROE has changed -62.79% with respect to the historical average. Over the past ten years (40 quarters), AVXL's ROE was at its highest in in the December 2023 quarter at -6.36%. The ROE was at its lowest in in the September 2014 quarter at -5035.17%.
Average
-82.30%
Median
-70.34%
Minimum
-233.61%
Maximum
-25.14%
Anavex Life Sciences Corp. (AVXL) ROE by Quarter and Year
Discovering the peaks and valleys of Anavex Life Sciences Corp. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 147.14%
Maximum Annual ROE = -25.14%
Minimum Annual Increase = -98.40%
Minimum Annual ROE = -233.61%
| Year | ROE | Change |
|---|---|---|
| 2024 | -35.76% | 6.77% |
| 2023 | -33.49% | -0.54% |
| 2022 | -33.67% | 33.96% |
| 2021 | -25.14% | -73.95% |
| 2020 | -96.49% | -25.55% |
| 2019 | -129.60% | 52.16% |
| 2018 | -85.17% | 53.47% |
| 2017 | -55.50% | -76.24% |
| 2016 | -233.61% | 147.14% |
| 2015 | -94.53% | -98.40% |
Anavex Life Sciences Corp. (AVXL) Average ROE
How has AVXL ROE performed in the past?
The current ROE of Anavex Life Sciences Corp. (AVXL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-34.31%
5-year avg
-44.91%
10-year avg
-82.30%
Anavex Life Sciences Corp. (AVXL) ROE vs. Peers
How is AVXL’s ROE compared to its peers?
Anavex Life Sciences Corp.’s ROE is greater than Cassava Sciences, Inc. (-12.36%), greater than INmune Bio, Inc. (-115.51%), greater than BioVie Inc. (-188.95%), greater than Cognition Therapeutics, Inc. (-150.93%), less than Annovis Bio, Inc. (874.76%), greater than Iovance Biotherapeutics, Inc. (-58.43%), greater than Axsome Therapeutics, Inc. (-234.35%), less than Novavax, Inc. (44.82%), less than Exelixis, Inc. (21.26%), greater than TG Therapeutics, Inc. (-8.32%), greater than Viking Therapeutics, Inc. (-12.73%), greater than Madrigal Pharmaceuticals, Inc. (-71.78%), less than BioXcel Therapeutics, Inc. (98.33%), less than Reviva Pharmaceuticals Holdings, Inc. (1.15%), greater than Eyenovia, Inc. (-1243.79%), greater than TransCode Therapeutics, Inc. (-649.01%), greater than Kodiak Sciences Inc. (-84.52%),
| Company | ROE | Market cap |
|---|---|---|
| -12.36% | $110.17M | |
| -115.51% | $100.44M | |
| -188.95% | $37.40M | |
| -150.93% | $25.70M | |
| 874.76% | $65.76M | |
| -58.43% | $2.26B | |
| -234.35% | $4.18B | |
| 44.82% | $1.38B | |
| 21.26% | $9.62B | |
| -8.32% | $5.02B | |
| -12.73% | $4.69B | |
| -71.78% | $6.81B | |
| 98.33% | $16.81M | |
| 1.15% | $57.25M | |
| -1243.79% | $9.47M | |
| -649.01% | $2.37M | |
| -84.52% | $512.29M |
Build a custom stock screener for Anavex Life Sciences Corp. (AVXL) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Anavex Life Sciences Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Anavex Life Sciences Corp. (AVXL) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Anavex Life Sciences Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Anavex Life Sciences Corp.'s ROE?
How is the ROE calculated for Anavex Life Sciences Corp. (AVXL)?
What is the highest ROE for Anavex Life Sciences Corp. (AVXL)?
What is the 3-year average ROE for Anavex Life Sciences Corp. (AVXL)?
What is the 5-year average ROE for Anavex Life Sciences Corp. (AVXL)?
How does the current ROE for Anavex Life Sciences Corp. (AVXL) compare to its historical average?